DoMore Diagnostics
DoMore Diagnostics develops Histotype Px® Colorectal, a CE-IVDD deep-learning biomarker that analyzes H&E histology slides to predict outcomes and guide adjuvant chemotherapy decisions for stage II/III colorectal cancer patients, distributed through Paige, PathAI, Sectra, and Proscia.
- Company typePrivate
- Founded2020
- HeadquartersOslo, Norway
- Headcount1–10
- GTM typeB2B
- OfferingSoftware
What DoMore Diagnostics does
DoMore Diagnostics is a Norwegian AI-powered digital pathology company that has developed Histotype Px® Colorectal, a CE-IVDD marked deep learning biomarker that analyzes standard H&E-stained whole-slide images to predict outcomes and adjuvant chemotherapy (ACT) benefit for stage II and III colorectal cancer patients. The algorithm stratifies patients into Low, Intermediate, and High-risk groups, and was originally published in The Lancet (2020) with extended results in The Lancet Oncology (2022); the underlying intellectual property is held under a global exclusive license from Oslo University Hospital's Institute for Cancer Genetics and Informatics (ICGI), where the CTO and the late Prof. Håvard Danielsen co-developed the method. The company is built on research from Oslo University Hospital, Oxford University, and University College London, and was selected as a Lighthouse project by the Norwegian Research Council.
The product analyzes routine histology slides with no additional tissue or wet-lab work required, and can be combined with circulating tumor DNA (ctDNA) minimal residual disease testing — a combination validated in the CIRCULATE-Japan GALAXY trial (n=1,082) and forthcoming CIRCULATE-FRANCE PRODIGE 70 study (n=500). Histotype Px® is offered as a CE-IVDD clinical product in the EU and as Research Use Only elsewhere, with three granted US patents and first patents in Japan and Korea protecting the method across major oncology markets. Internally, the company has AI Engineers, a Senior Software Developer, a Product Manager, a Head of Quality and Regulatory, and a Medical Director, and a Scientific Advisory Board that includes international KOLs from UMC Utrecht, Mayo Clinic, and the NCC Japan.
Commercially, DoMore Diagnostics operates a hybrid go-to-market: a direct quote-based test-ordering channel via its website and distribution through four major digital pathology platforms — Paige's AppLab™ Marketplace, PathAI's AISight™ Image Management System, Sectra's Amplifier Marketplace, and Proscia's Concentriq® Dx — giving the small team access to the largest installed bases of digital pathology customers globally. Revenue is generated from per-test fees and platform licensing economics, with the largest single capital event being up to €10 million in EIC Accelerator financing (€2.5M grant + up to €7.5M equity) awarded in February 2024 alongside a NOK 16M Research Council of Norway grant. The current commercial footprint is EU-focused under CE-IVDD, with research collaborations and validation work extending into the US, the Netherlands, Denmark, France, and Japan ahead of broader regulatory clearance.
DoMore Diagnostics firmographics
Firmographics- Name
- DoMore Diagnostics
- Legal name
- DoMore Diagnostics AS
- Website
- https://domorediagnostics.com
- Company type
- Private
- Founded year
- 2020
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- DoMore Diagnostics develops Histotype Px® Colorectal, a CE-IVDD deep-learning biomarker that analyzes H&E histology slides to predict outcomes and guide adjuvant chemotherapy decisions for stage II/III colorectal cancer patients, distributed through Paige, PathAI, Sectra, and Proscia.
- Ownership category
- akta.pro rank
DoMore Diagnostics industry classification
Industry- Product category
- Digital Pathology Diagnostics
- NAICS
- Medical and Diagnostic Laboratories (62151), In-Vitro Diagnostic Substance Manufacturing (325413)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835)
- akta.pro primary industry
- Molecular Pathology & Tissue Biomarkers (IHC/ISH, digital pathology-linked markers) (HLAAAMAI)
- akta.pro secondary industries
- Oncology Diagnostics (tumor profiling, MRD, liquid biopsy) (HLAAALAE), Prognostic & Risk Stratification Biomarkers (disease progression, recurrence risk) (HLAAAMAF)
Keywords
Where DoMore Diagnostics is headquartered
LocationHeadquarters
- HQ city
- Oslo
- HQ country
- Norway
- HQ region
- Europe
Offices1 record
Markets served
DoMore Diagnostics business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Others
Revenue model
- Histotype Px® Colorectal Test Sales: Revenue generated from laboratory test orders for Histotype Px® Colorectal digital biomarker analysis. Healthcare providers submit tumor tissue samples for AI-powered analysis that predicts patient outcomes and guides adjuvant chemotherapy decisions. The test is available through direct ordering on the company website and through integrated pathology platforms.
- Platform Licensing: Technology licensing arrangements with digital pathology platform providers (Paige, PathAI, Sectra, Proscia) enabling integration of Histotype Px® into their enterprise pathology platforms, potentially generating licensing fees or revenue sharing.
Go-to-market motion3 records
Distribution channels5 records
Marketing channels6 records
DoMore Diagnostics product offering
Product offeringCore offering
DoMore Diagnostics develops and sells Histotype Px Colorectal, a CE-IVDD marked deep learning digital biomarker that analyzes routine H&E-stained whole-slide histology images to predict patient outcomes and guide adjuvant chemotherapy treatment decisions for stage II and III colorectal cancer patients. The product classifies patients into Low, Intermediate, and High-risk groups and is delivered either as a cloud-based analysis service or through integration with major enterprise digital pathology platforms (Paige, PathAI, Sectra, Proscia) for use by hospital pathology laboratories.
Product overview
DoMore Diagnostics offers a single unified product: the Histotype Px Colorectal digital biomarker. This AI-powered tool analyzes routine hematoxylin and eosin (H&E) stained histology slides to predict patient outcomes and guide personalized adjuvant chemotherapy decisions for colorectal cancer patients. The product is delivered as a cloud-based or platform-integrated clinical decision support tool that can be accessed through commercial partnerships with digital pathology platform providers including Proscia (Concentriq Dx), Sectra, PathAI (AISight), and Paige (AppLab Marketplace).
Differentiator
Problem solved
Functional benefit
Products and services
- Histotype Px Colorectal
Quantifiable outcome
- Stage II/III colorectal cancer patients risk-stratified into Low, Intermediate, and High-risk groups for adjuvant chemotherapy decisions
- +4 more outcomes
Companies that use DoMore Diagnostics
Customer profileNamed customers6 records
Segments3 records
Ideal customer profiles2 records
DoMore Diagnostics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration4 records
AI capability3 records
Feature3 records
DoMore Diagnostics partnerships and signals
Strategic signalPartnerships
Twelve partnerships are on record, tiered strategic, core and supporting.
- FFCD and CHU DijonstrategicCollaboration with French-speaking Federation of Digestive Cancer (FFCD) and CHU Dijon to clinically validate Histotype Px® Colorectal using samples from the CIRCULATE-FRANCE PRODIGE 70 clinical trial in 500 colorectal cancer patients. Aims to evaluate prognostic performance alone and in combination with ctDNA.
- Aarhus University HospitalstrategicClinical research collaboration to assess prognostic and predictive value of Histotype Px® Colorectal alone and in combination with circulating tumor DNA in Danish stage II and III colorectal cancer patients with comprehensive ctDNA monitoring.
- PathAIcoreCommercial partnership making Histotype Px® Colorectal available on AISight™, PathAI's Image Management System for Digital Pathology. AISight is a cloud-native intelligent enterprise workflow solution used by leading laboratories worldwide for digital pathology workflows and AI applications.
- Erasmus MC Cancer InstitutestrategicResearch collaboration to clinically validate Histotype Px® Colorectal in up to 2200 stage II and III rectal cancer patients from Snapshot rectum 2011 and 2016 cohorts who have not received adjuvant chemotherapy. Supported by Innovation Project grant from Research Council of Norway.
- Gustave RoussystrategicClinical research collaboration with Europe's #1 and world's #4 ranked cancer hospital to clinically validate Histotype Px® Colorectal in French stage II and III colorectal cancer patients using H&E slides and matching biopsies with clinical outcome data.
- University Medical Centre Utrecht (UMC Utrecht)strategicResearch collaboration to clinically validate Histotype Px® Colorectal in up to 2500 stage II and III colon cancer patients from the PLCRC cohort. Study aims to generate data supporting clinical guideline inclusion and adoption as a digital biomarker to guide ACT treatment decisions.
- PaigecoreHistotype Px® Colorectal added to Paige's AppLab™ Marketplace, ensuring seamless and easy integration of AI solutions for end users. Paige is a key partner as DoMore continues mission to personalize cancer treatment for patients worldwide.
- Stavanger University HospitalsupportingCollaboration to validate Histotype Px® Colorectal in patients from the ACROBATICC study and test clinical utility of the digital biomarker in Norwegian colorectal cancer patients.
- ProsciacorePartnership to integrate DoMore Diagnostics' CE-IVDD marked Histotype Px® Colorectal digital biomarker with Proscia's CE-IVDR marked Concentriq® Dx enterprise pathology platform. Collaboration enables AI-powered clinical decision support into routine pathology workflows for colorectal cancer patients.
- The Ohio State University Wexner Medical CenterstrategicRetrospective testing agreement to implement and validate Histotype Px® Colorectal in U.S. patients to determine whether the test can help guide real-life decisions for patients with stage II and III colorectal cancer.
- SectracoreIntegration of Histotype Px® Colorectal with Sectra's pathology imaging platform via Sectra Amplifier Marketplace, giving Sectra users access to Histotype Px within their existing digital pathology workflow.
- Oslo University Hospital / ICGIcoreDoMore Diagnostics is based on research from the Institute for Cancer Genetics and Informatics (ICGI) at Oslo University Hospital. The company holds global exclusive license to the patent portfolio underpinning Histotype Px. Ongoing collaboration aims to develop new and better digital biomarkers that are robust for lab and scanner variations.
Scale indicators4 records
Recent moves6 records
Expansion highlights6 records
DoMore Diagnostics competitors and assessment
Company assessmentMarket position
Competitive moat5 records
Key highlights7 records
Customer concentration
DoMore Diagnostics social profiles
Digital presenceDoMore Diagnostics compliance and trust
Trust signalCompliance2 records
DoMore Diagnostics financial estimates
Financial estimateRevenue estimate
Valuation estimate
DoMore Diagnostics leadership team
Management profileNumber of profiles
Profiles15 records
DoMore Diagnostics funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
DoMore Diagnostics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about DoMore Diagnostics
What does DoMore Diagnostics do?
DoMore Diagnostics develops and sells Histotype Px Colorectal, a CE-IVDD marked deep learning digital biomarker that analyzes routine H&E-stained whole-slide histology images to predict patient outcomes and guide adjuvant chemotherapy treatment decisions for stage II and III colorectal cancer patients. The product classifies patients into Low, Intermediate, and High-risk groups and is delivered either as a cloud-based analysis service or through integration with major enterprise digital pathology platforms (Paige, PathAI, Sectra, Proscia) for use by hospital pathology laboratories.
Is DoMore Diagnostics a public or private company?
DoMore Diagnostics is a private company. It is classified as venture growth investor backed and is currently operating.
When was DoMore Diagnostics founded?
DoMore Diagnostics was founded in 2020. It employs 1 to 10 people.
Where is DoMore Diagnostics based?
DoMore Diagnostics is headquartered in Oslo, Norway, in the Europe region.
How does DoMore Diagnostics make money?
Two revenue lines are on record. Histotype Px® Colorectal Test Sales are the primary driver. The others are platform Licensing.
Does DoMore Diagnostics have an API?
No public API is recorded for DoMore Diagnostics.
What industry is DoMore Diagnostics in?
DoMore Diagnostics's product category is Digital Pathology Diagnostics. Its primary akta.pro industry code is HLAAAMAI, Molecular Pathology & Tissue Biomarkers (IHC/ISH, digital pathology-linked markers), with a secondary code of HLAAALAE, Oncology Diagnostics (tumor profiling, MRD, liquid biopsy). Its NAICS code is 62151 and its SIC code is 2835.